As GSK-3β is a positive regulator of NF-κB activity (Ougolkov et al, 2005, 2007), inhibition of GSK-3 may sensitise renal cancer cells to conventional chemotherapeutic agents. The gene discussed is NFKB1; the disease is renal carcinoma.